{"id":4157,"date":"2026-11-07T09:00:00","date_gmt":"2026-11-07T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4157"},"modified":"2026-11-07T16:14:37","modified_gmt":"2026-11-07T20:14:37","slug":"saturday-rounds-week-of-october-31-november-6-2026","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4157","title":{"rendered":"Saturday Rounds: Week of October 31\u2013November 6, 2026"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261107_Insilens_Saturday_Rounds-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4158\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261107_Insilens_Saturday_Rounds-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261107_Insilens_Saturday_Rounds-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261107_Insilens_Saturday_Rounds-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261107_Insilens_Saturday_Rounds-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261107_Insilens_Saturday_Rounds.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Long-term safety catches up with the platforms.<\/strong><\/p>\n<p>Weekly Biotech Signal Review \u00b7 Completed reporting week: October 31\u2013November 6, 2026 \u00b7 Published November 7, 2026<\/p>\n<p><strong>Report at a glance:<\/strong> Novartis confirmed nine tumor cases after Zolgensma, a Nature Genetics paper tied CAR-T to clonal expansion in the marrow, Ultragenyx stopped two programs and cut about 20% of staff, and Karyopharm filed Chapter 11, in a week when XBI fell 2.42% and the S&amp;P 500 lost 2.68%.<\/p>\n<h3>The Lede<\/h3>\n<p>Novartis confirmed nine tumor reports in children treated with the SMA gene therapy Zolgensma since 2019, two of which show vector DNA integrated near the GLI1 oncogene, and the FDA said it is evaluating the adequacy of the prescribing information and long-term follow-up. In the same week a Nature Genetics paper (Hamilton, Phillips, Alizadeh) reported that clonal hematopoiesis expands after CD19 CAR-T therapy and that the CAR vector often integrates into pre-existing clones. Ultragenyx ended GTX-102 (Angelman) after a Phase 3 miss and UX701 (Wilson disease) and cut about 20% of its workforce; Sarepta decided not to restart the paused ENVISION trial; Karyopharm entered Chapter 11 with Ayrmid as stalking-horse bidder. Biotech sold off with the market on Thursday: XBI fell 2.42% over the week (155.98 to 152.21) and the S&amp;P 500 fell 2.68%.<\/p>\n<table>\n<thead>\n<tr>\n<th>Signal Importance<\/th>\n<th>Signal Direction<\/th>\n<th>Confidence in Facts<\/th>\n<th>Confidence in Interpretation<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>4 \/ 5<\/td>\n<td>Negative for vector-based platform safety narratives; mixed for capital access<\/td>\n<td>High on events, Moderate on tumor causality<\/td>\n<td>Moderate<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><em>Weekly validation gate: importance is 4\/5 because post-marketing and translational safety data now bear on two of the largest gene- and cell-therapy modalities at once. Interpretation is moderate because Novartis\u2019 count is not a rate, causality is established in only two integration cases, and the Nature Genetics paper is observational with no independent replication yet.<\/em><\/p>\n<h3>Signal of the Week: Vector Integration Moves From Theory to Case Reports<\/h3>\n<p>Novartis has logged nine tumor reports in Zolgensma-treated children since approval in 2019. In two of them, integration sat near GLI1 and the highest vector DNA levels were found in the liver; the mechanism in a third case remains under investigation. Novartis says tumor risk from vector integration is already in the label and that benefit-risk remains positive, while the FDA is evaluating label adequacy and long-term follow-up. Sources report that more than 6,000 patients have been treated, so the reported cases are rare, but the denominator and follow-up duration are not yet defined.<\/p>\n<p>The Nature Genetics study points the same way in a different modality: prolonged cytopenias after CAR19 therapy were associated with clonal cytopenias of undetermined significance and interferon-driven marrow inflammation, and the CAR vector frequently integrated into pre-existing clonal hematopoiesis. The strongest counterargument is that both findings are small-number, observational signals; most Zolgensma recipients and most CAR-T recipients have no reported tumor, and integration near an oncogene is not proof of causation in every case.<\/p>\n<h3>The Week in Five<\/h3>\n<p><strong>Regulatory<\/strong> \u2014 The FDA granted RMAT designation to CRISPR Therapeutics\u2019 CTX310 for severe hypertriglyceridemia and for patients with elevated LDL-C, according to the company\u2019s Q3 release; the release also announces a late-breaking oral presentation of Phase 1b sHTG data at AHA Scientific Sessions 2026 (the session date was not confirmed in our check). BeOne reported that the FDA granted Priority Review to the MANGROVE filing in first-line mantle cell lymphoma and that interim results are slated for the ASH 2026 plenary session. Separately, the FDA is evaluating Zolgensma labeling and follow-up (above).<\/p>\n<p><strong>Clinical<\/strong> \u2014 Ultragenyx said its Phase 3 GTX-102 study in Angelman syndrome failed to show efficacy, which management attributed to variation in the control group across endpoints, and that UX701 did not meet criteria to move to Phase 3; both programs are ending. Sarepta said on its Q3 call (November 5\u20136) it will not resume enrollment in ENVISION, which was paused for over a year and had recruited roughly half its intended sample; CureDuchenne reports the study will close with analysis of blinded Part 1 data. Sanofi discontinued the Phase 1 STAT6 degrader SAR448272 (partnered with Nurix) on nonclinical findings it said did not justify further eczema development; Nurix shares fell by roughly 30\u201340% depending on the source, and the company says its runway into the second half of 2029 is unchanged.<\/p>\n<p><strong>Deals<\/strong> \u2014 Boehringer Ingelheim signed an option-based alliance with Sino Biopharmaceutical (now SBP Group) on six preclinical oncology programs (ADCs and T-cell engagers): $358 million in upfront and near-term payments and up to about $7 billion in milestones plus royalties. Novartis terminated its BrainTransporter agreement with BioArctic (announced November 2) because it dropped its own antibody program; BioArctic keeps the $30 million upfront and says the decision is unrelated to its platform.<\/p>\n<p><strong>Platform<\/strong> \u2014 The Hamilton CAR19 clonal hematopoiesis paper and the Zolgensma integration cases both concern vector integration into expanded or oncogene-adjacent loci. Neither undermines efficacy in approved indications, but both raise the value of long-term registry and integration-site surveillance. A companion Nature Genetics commentary describes post-CAR hematotoxicity as a hidden legacy of therapy.<\/p>\n<p><strong>China<\/strong> \u2014 The Boehringer\u2013SBP alliance is the largest China-sourced option structure of the week, built on six programs that are all preclinical, with Boehringer opt-in after undisclosed clinical milestones. Other China items in the reference file (including the camrelizumab\/rivoceranib item and the Imunopharm IM19 approval) could not be confirmed and are not reported.<\/p>\n<h3>The Analyst\u2019s Take<\/h3>\n<p>Observed pattern: the week combined late safety signals for vector-based therapies with decisive program attrition. Ultragenyx, Sanofi\/Nurix, Novartis\/BioArctic and Sarepta each ended or declined to continue a program, and in each case the company framed the decision as program-specific. Taken individually that framing is plausible; taken together it shows partners and sponsors cutting earlier when proof points slip.<\/p>\n<p>Explicit inference: capital remains available for programs with a clear regulatory path, and it attaches to structures that defer risk. Boehringer\u2019s alliance pays $358 million against about $7 billion of contingent value, Rapport and Lyell raised money on clinical progress, and Karyopharm\u2019s restructuring leaves equity holders with nothing. A competing interpretation is that the week\u2019s moves reflect market beta: biotech fell 4\u20137% in a single session on a broad AI-related selloff and partly rebounded on Friday. Confirmation of the selectivity thesis would need the same dispersion to persist when indices recover.<\/p>\n<h3>Evidence Classification<\/h3>\n<table>\n<thead>\n<tr>\n<th>Verified facts<\/th>\n<th>Company claims<\/th>\n<th>Explicit inference<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Nine Zolgensma tumor reports and the FDA evaluation, the Hamilton paper\u2019s findings, Ultragenyx\u2019s restructuring and program decisions, Sarepta\u2019s ENVISION decision, Sanofi\u2019s discontinuation, Novartis\u2019 termination of the BioArctic deal, Karyopharm\u2019s Chapter 11 filing, the Boehringer\u2013SBP terms and the Rapport and Lyell financings were checked against company releases, SEC-linked sources, the journal and named trade press.<\/td>\n<td>Novartis\u2019 benefit-risk statement, Ultragenyx\u2019s control-group explanation, Sanofi\u2019s nonclinical rationale, BeOne\u2019s Priority Review and ASH plenary timing, CRISPR\u2019s RMAT and AHA statements, and Karyopharm\u2019s DIP size are sponsor statements.<\/td>\n<td>\u201cSafety catches up with platforms\u201d and the reading of option structures as risk deferral are interpretations.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>Market &amp; Capital Pulse<\/h3>\n<p><strong>Observed market facts<\/strong><\/p>\n<p>Measurement window: Friday, October 30 close to Friday, November 6 close. XBI fell 2.42% (155.98 to 152.21), and the S&amp;P 500 index fell 2.68% (to a Friday close of 7,376.86 after a 4.4% drop on Thursday), so XBI lost about 0.26 points less than the index. Within the week XBI closed at 159.10 on Wednesday, fell 6.7% to 148.40 on Thursday, then rose 2.6% on Friday. IBB closed at a record 221.13 on Wednesday and 209.99 on Thursday; we could not confirm a Friday close for IBB or a SPY ETF close, so no weekly IBB or SPY figure is reported (the reference file\u2019s figures are not independently verified).<\/p>\n<p><strong>Capital and strategic appetite<\/strong><\/p>\n<p>Public follow-ons and private placements: Rapport Therapeutics raised about $410.7 million across a common-stock offering at $21.00, $172.5 million of 2.25% convertible notes due 2032 and a concurrent private placement, and now reports about $815.4 million of liquidity; Lyell sold about 7.43 million shares at $10.77 for roughly $80 million (ARCH, Adage, Caligan, RTW), funding ronde-cel toward a planned BLA in the second half of 2027. Together about $490.7 million. Contraction: Ultragenyx cut about 20% of its workforce (to roughly 1,000 employees, about $25 million of charges) and Karyopharm filed Chapter 11 with up to $55 million of new DIP money (some sources report a $110 million facility including roll-up; the primary filing was not reconciled).<\/p>\n<p>Inference, not causation: the market paid for programs with near-term regulatory or clinical catalysts and punished those whose proof points slipped, but a one-week sample dominated by a broad selloff cannot separate selection from beta.<\/p>\n<h3>Deal Appetite and Restructuring<\/h3>\n<p>One new alliance carried about $7.4 billion of maximum disclosed value: Boehringer\u2013SBP, $358 million of upfront and near-term cash against roughly $7 billion in milestones, covering six preclinical assets. Two partnerships ended: Sanofi\u2013Nurix (SAR448272; Nurix loses an estimated $453 million of prospective milestone value according to one source) and Novartis\u2013BioArctic (BioArctic retains $30 million; sources differ on the deal\u2019s headline value, $772 million versus $802 million).<\/p>\n<p>Restructurings: Ultragenyx (about 20% workforce reduction, GTX-102 and UX701 ended) and Karyopharm (Chapter 11, existing equity cancelled, Ayrmid stalking-horse for a merger giving its holders 55% of the combined company; close targeted for Q1 2027, subject to auction and court approval). The reference file\u2019s leadership changes could not be verified and none are reported.<\/p>\n<h3>By the Numbers<\/h3>\n<table>\n<thead>\n<tr>\n<th>Category<\/th>\n<th>Verified count or value<\/th>\n<th>Scope note<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>FDA approvals<\/td>\n<td>0<\/td>\n<td>No approvals identified in the window.<\/td>\n<\/tr>\n<tr>\n<td>Major regulatory actions<\/td>\n<td>3<\/td>\n<td>CTX310 RMAT designations (sHTG, elevated LDL-C; counted as one action); MANGROVE Priority Review; FDA evaluation of Zolgensma labeling.<\/td>\n<\/tr>\n<tr>\n<td>Decisions and readouts<\/td>\n<td>4<\/td>\n<td>GTX-102 miss; UX701 ended; Sarepta ENVISION not resumed; Sanofi STAT6 discontinuation.<\/td>\n<\/tr>\n<tr>\n<td>New license \/ option deals<\/td>\n<td>1<\/td>\n<td>Boehringer\u2013SBP: $358M upfront and near-term; up to about $7B milestones.<\/td>\n<\/tr>\n<tr>\n<td>Partnership terminations<\/td>\n<td>2<\/td>\n<td>Sanofi\u2013Nurix SAR448272; Novartis\u2013BioArctic.<\/td>\n<\/tr>\n<tr>\n<td>Public financings<\/td>\n<td>2 \/ about $490.7M<\/td>\n<td>Rapport about $410.7M (stock, converts, private placement); Lyell about $80M.<\/td>\n<\/tr>\n<tr>\n<td>Material restructurings<\/td>\n<td>2<\/td>\n<td>Ultragenyx ~20% workforce cut; Karyopharm Chapter 11.<\/td>\n<\/tr>\n<tr>\n<td>Leadership changes<\/td>\n<td>0 verified<\/td>\n<td>Reference-file items not verified.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>Watching Next Week<\/h3>\n<p>Resolution of last week\u2019s calendar: SITC 2026 (Phoenix) ran November 4\u20138 as scheduled. We did not verify the outcomes of Agios\u2019 Q3 update, Editas\u2019 AHA presentation, the Bambusa and Aspen IPO closings, or the INO-3107 result, and they are not reported here.<\/p>\n<table>\n<thead>\n<tr>\n<th>Date<\/th>\n<th>Catalyst<\/th>\n<th>Evidence status<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Nov 8<\/td>\n<td>SITC 2026 Annual Meeting closes<\/td>\n<td>Confirmed on the SITC site.<\/td>\n<\/tr>\n<tr>\n<td>Nov 14<\/td>\n<td>FDA PDUFA goal date: ivonescimab (Summit), EGFR-mutated non-squamous NSCLC<\/td>\n<td>Listed by a catalyst aggregator; confirm against Summit\u2019s disclosures. The reference file\u2019s aficamten date could not be confirmed.<\/td>\n<\/tr>\n<tr>\n<td>AHA 2026<\/td>\n<td>CTX310 late-breaking oral presentation (CRISPR)<\/td>\n<td>Company release confirms the presentation; session date not confirmed.<\/td>\n<\/tr>\n<tr>\n<td>Dec 2026<\/td>\n<td>Karyopharm final DIP order (within 35 days of filing) and auction (within 60 days if needed)<\/td>\n<td>From reporting on plan milestones; the court\u2019s rulings are pending.<\/td>\n<\/tr>\n<tr>\n<td>Dec 2026<\/td>\n<td>BeOne MANGROVE interim analysis, ASH plenary<\/td>\n<td>BeOne Q3 release (secondary summary); exact session date not confirmed in our check.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>What Would Change Our View<\/h3>\n<p><strong>Upgrade<\/strong> \u2014 Registry or FDA review data showing tumor incidence well below an elevated background rate across more than 6,000 Zolgensma recipients, and prospective CAR-T follow-up showing clonal expansion is not associated with secondary myeloid cancers, would restore confidence in vector durability.<\/p>\n<p><strong>Downgrade<\/strong> \u2014 Additional integration-linked tumors in Zolgensma or other AAV products, or FDA label restrictions and screening requirements, would convert program-specific cautions into class-level development constraints.<\/p>\n<p><strong>Falsify<\/strong> \u2014 Independent datasets showing CAR-T clonal expansion reflects baseline clonal hematopoiesis without vector involvement would falsify the view that integration is a meaningful safety variable for cell-therapy platforms.<\/p>\n<h3>Evidence Base<\/h3>\n<p><em>Sources are listed in order of first citation. Discrepancies versus the reference file used for this edition: Karyopharm\u2019s DIP size is reported as up to $55 million (company release) and up to $110 million (other outlets); BioArctic\u2013Novartis headline deal value is $772 million or $802 million depending on the outlet; the reference file\u2019s XBI close (152.21) matched our independent check, but its IBB and SPY closes could not be confirmed (IBB closed at 209.99 on Nov 5; the S&amp;P 500 index closed at 7,376.86 on Nov 6, down 2.68% on the week); the BeOne MANGROVE hazard ratio of 0.57 was not found in the sources we checked; the Imunopharm IM19 approval and the aficamten\/MAPLE-HCM November 14 PDUFA were not confirmable. Left out as unverified: Nxera\u2013AbbVie, Precision Bio and INOVIO financings, private rounds, Evommune, SER-155 as a new event (the 80% irEC response was reported in July; Seres\u2019 Nov 3 release covers development plans only), leadership changes, Kamau\/SELLAS\/Cantargia\/Iksuda\/A2\/Tiziana\/Taiho\/J&amp;J icotrokinra readouts, Hinova VAV1, Legend and Syndax calendar items, CRISPR ACR\/AHA dates, and the Pregene and Hengrui China items.<\/em><\/p>\n<ol>\n<li><a href=\"https:\/\/www.genengnews.com\/topics\/genome-editing\/novartis-confirms-nine-cases-of-tumors-in-children-treated-with-gene-therapy-zolgensma\/\">GEN, Novartis Confirms Nine Cases of Tumors in Children Treated with Gene Therapy Zolgensma<\/a><\/li>\n<li><a href=\"https:\/\/www.fiercepharma.com\/pharma\/novartis-confirms-more-reported-tumor-cases-zolgensma-patients-sma-groups-seek-details\">Fierce Pharma, Novartis confirms more reported tumor cases in Zolgensma patients as SMA groups seek details<\/a><\/li>\n<li><a href=\"https:\/\/www.sma-europe.eu\/news\/information-regarding-recent-zolgensma-safety-concerns\">SMA Europe, Information regarding recent Zolgensma safety concerns<\/a><\/li>\n<li><a href=\"https:\/\/www.nature.com\/articles\/s41588-026-02795-5\">Nature Genetics, Clonal hematopoiesis and cytopenias following CAR19 therapy<\/a><\/li>\n<li><a href=\"https:\/\/www.nature.com\/articles\/s41588-026-02805-6\">Nature Genetics, Hematotoxicity: the hidden legacy of CAR T cell therapy<\/a><\/li>\n<li><a href=\"https:\/\/ir.ultragenyx.com\/news-releases\/news-release-details\/ultragenyx-reports-third-quarter-2026-financial-results\">Ultragenyx, Third Quarter 2026 Financial Results and Expense Reductions<\/a><\/li>\n<li><a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/0001515673\/000119312526445342\/rare-ex99_1.htm\">Ultragenyx, Form 8-K Exhibit 99.1 (SEC)<\/a><\/li>\n<li><a href=\"https:\/\/www.gurufocus.com\/news\/9175535\/ultragenyx-pharmaceutical-inc-rare-q3-2026-earnings-call-highlights-gene-therapy-launches-pipeline-cuts-and-a-clearer-path-to-2027-profitability\">GuruFocus, Ultragenyx Q3 2026 Earnings Call Highlights<\/a><\/li>\n<li><a href=\"https:\/\/cureduchenne.org\/research\/sarepta-shares-updates-with-the-duchenne-community-including-decision-to-close-the-envision-gene-therapy-clinical-trial\/\">CureDuchenne, Sarepta shares updates with the Duchenne community, including decision to close the ENVISION trial<\/a><\/li>\n<li><a href=\"https:\/\/www.fool.com\/earnings\/call-transcripts\/2026\/11\/06\/sarepta-srpt-q3-2026-earnings-call-transcript\/\">Motley Fool, Sarepta Q3 2026 Earnings Call Transcript (Nov 6, 2026)<\/a><\/li>\n<li><a href=\"https:\/\/www.fiercebiotech.com\/biotech\/sanofi-scraps-stat6-degrader-nurix-just-2-months-after-entering-clinic\">Fierce Biotech, Sanofi scraps STAT6 degrader from Nurix just 2 months after entering clinic<\/a><\/li>\n<li><a href=\"https:\/\/www.biopharmadive.com\/news\/sanofi-discontinue-development-nurix-stat6-degrader-eczema\/873697\/\">BioPharma Dive, Sanofi stops development of Nurix-partnered immune drug<\/a><\/li>\n<li><a href=\"https:\/\/www.prnewswire.com\/news-releases\/bioarctic-collaborator-novartis-terminates-agreement-302926959.html\">BioArctic, Collaborator Novartis terminates agreement (PR Newswire)<\/a><\/li>\n<li><a href=\"https:\/\/european-biotechnology.com\/latest-news\/novartis-ends-bioarctic-brain-delivery-deal-worth-up-to-802m\/\">European Biotechnology Magazine, Novartis ends BioArctic brain-delivery deal worth up to $802M<\/a><\/li>\n<li><a href=\"https:\/\/investors.karyopharm.com\/2026-11-02-Karyopharm-Therapeutics-Inc-Announces-Planned-Merger-with-Ayrmid-Ltd-to-Strengthen-Company-for-the-Future\">Karyopharm, Announces Planned Merger with Ayrmid Ltd. (Nov 2, 2026)<\/a><\/li>\n<li><a href=\"https:\/\/www.tradingview.com\/news\/tradingview:334df689e0f52:0-karyopharm-restructuring-deal-backs-ayrmid-sale-and-110-million-dip-facility\/\">TradingView, Karyopharm Restructuring Deal Backs Ayrmid Sale and $110 Million DIP Facility<\/a><\/li>\n<li><a href=\"https:\/\/pharmaphorum.com\/news\/boehringer-forges-7bn-alliance-chinas-sbp-group\">pharmaphorum, Boehringer forges $7bn alliance with China\u2019s SBP Group<\/a><\/li>\n<li><a href=\"https:\/\/biospace.com\/deals\/boehringer-bets-big-on-china-offering-7b-biobucks-for-sino-cancer-programs\">BioSpace, Boehringer bets big on China, offering $7B biobucks for Sino cancer programs<\/a><\/li>\n<li><a href=\"https:\/\/www.biospace.com\/press-releases\/rapport-announces-closing-of-public-offerings-of-common-stock-and-pre-funded-warrants-and-convertible-notes-including-full-exercise-of-underwriters-options-to-purchase-additional-shares-and-notes-as-well-as-concurrent-private-placement\">BioSpace, Rapport Announces Closing of Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Notes<\/a><\/li>\n<li><a href=\"https:\/\/www.manilatimes.net\/2026\/11\/04\/tmt-newswire\/globenewswire\/lyell-immunopharma-announces-80-million-private-placement-to-advance-ronde-cel-toward-planned-bla-submission\/2461856\/amp\">Lyell Immunopharma, $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission (Manila Times\/GlobeNewswire)<\/a><\/li>\n<li><a href=\"https:\/\/ir.crisprtx.com\/news-releases\/news-release-details\/crispr-therapeutics-provides-business-update-and-reports-third-7\">CRISPR Therapeutics, Third Quarter 2026 Financial Results<\/a><\/li>\n<li><a href=\"https:\/\/swissnewsnow.com\/beone-q3-2026-results-guidance\/1830557\">BeOne Medicines, Third Quarter 2026 Financial Results and Business Updates (secondary summary)<\/a><\/li>\n<li><a href=\"https:\/\/www.sitcancer.org\/home\">SITC, Annual Meeting 2026 (Phoenix)<\/a><\/li>\n<li><a href=\"https:\/\/www.biopharmawatch.com\/fda-calendar\">BioPharmaWatch, Biotech Catalysts to Watch (PDUFA calendar, aggregator)<\/a><\/li>\n<li><a href=\"https:\/\/finance.yahoo.com\/quote\/XBI\/\">Yahoo Finance, XBI quote and history (Nov 6 close 152.21)<\/a><\/li>\n<li><a href=\"https:\/\/www.heygotrade.com\/en\/us-stock\/xbi\/\">HeyGoTrade, XBI Stock Price (Nov 4 close)<\/a><\/li>\n<li><a href=\"https:\/\/www.ishares.com\/us\/products\/239699\/ishares-biotechnology-etf\">iShares, Biotechnology ETF (IBB) fund page (Nov 5 close and NAV)<\/a><\/li>\n<li><a href=\"https:\/\/247wallst.com\/investing\/2026\/11\/07\/the-sp-500-just-had-its-worst-week-since-the-april-2025-tariff-crash\/\">24\/7 Wall St., The S&amp;P 500 Just Had Its Worst Week Since the April 2025 Tariff Crash<\/a><\/li>\n<li><a href=\"https:\/\/stockanalysis.com\/etf\/xbi\/history\/\">StockAnalysis.com, XBI price history (Oct 30, 2026 close)<\/a><\/li>\n<\/ol>\n<p>Until next Saturday: follow the evidence, not the noise.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>); exact session date not confirmed in our check. What Would Change Our View Upgrade \u2014 Registry or FDA review data showing tumor incidence well below an elevated background rate across more than 6,000&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4158,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[250,251,249],"class_list":["post-4157","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-weekly-market-insight","tag-biotech-markets","tag-ma","tag-weekly-digest"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4157","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4157"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4157\/revisions"}],"predecessor-version":[{"id":4159,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4157\/revisions\/4159"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4158"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4157"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4157"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4157"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}